Hos cirrosepatienter med moderat nedsat leverfunktion (klassificeret som Child Pugh B) steg det gennemsnitlige AUC for rivaroxaban signifikant med 2, 3 gange sammenlignet med raske frivillige.
In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers.